Interviews

Paul G. Richardson, MD, discusses the SUCCESSOR-2 trial of mezigdomide, carfilzomib, and dexamethasone in multiple myeloma.

Early-phase clinical trials involving PIM-1 kinase inhibitors look promising.

Researchers launch a public immune atlas of pancreatic cancer therapy responses, allowing the public to rapidly link pancreatic cancer immunotherapy trials to immune shifts and outcomes.

PIM-1 kinase inhibitors in myelofibrosis offer new targets to overcome relapsed and refractory disease.

ctDNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA drops predict longer PFS.

CD25 rewires oncogene signaling in AML and ALL, revealing druggable complexes and a bold strategy: push pathways into toxic overdrive.

Dr Saad explores the emerging role of radiopharmaceuticals in prostate cancer.

Johns Hopkins Medicine develops a free immune atlas of pancreatic cancer trials, spotlighting blood-based signals to build stronger pancreatic cancer immunotherapy combinations.

Medicaid expansion has boosted breast cancer survival rates, especially for Hispanic women, highlighting ACA policy impact.

Experts weigh perioperative immunotherapy delays, rapid molecular testing, ctDNA MRD and emerging ADCs shaping early-stage lung cancer care.

Dr Ghatalia discusses RETAIN-2, highlighting ctDNA analysis drawn from RETAIN-1 and RETAIN-2.

Sagar Lonial, MD, discusses the significance of the MRD end point for the ongoing priority review of iberdomide in multiple myeloma.

In an interview, Vincent Ma, MD, discussed how ctDNA levels after the first cycle of immune checkpoint inhibitor in melanoma could shed light on clinical outcomes.

Using the best medication available in the frontline setting of RCC leads to optimal results.

Efficacy and safety results from the phase 1 PAnTHA study presented at 2026 ASCO GU.

Study reveals CD25 tunes tyrosine kinase signaling into a Goldilocks sweet spot, helping AML and ALL cells resist treatment and grow.

Understanding the safety profile of belzutifan (Welireg) will expand its use role in RCC.

TTLC 2026 spotlights next-gen lung cancer therapies, co-mutation strategies, and ctDNA monitoring—insights beyond CME for what’s coming next.

Sagar Lonial, MD, discusses the evolving role of cereblon E3 ligase modulators (CELMoDs) in the treatment of multiple myeloma.

Erica Pimenta, MD, PhD, discussed the goals and key findings from her and her colleagues’ research into IGF-1 and GLP-1 signaling pathways in liposarcoma.

New study links Medicaid expansion to sustained breast cancer survival gains, revealing uneven benefits by race and urging policy action.

Short-course enzalutamide in recurrent prostate cancer slashes PSA, but PSMA-PET tumor volume misleads, raising overtreatment concerns.

Rahul Banerjee, MD, discusses the rationale for potential therapeutic strategies to address T-cell exhaustion following CAR T-cell therapy in multiple myeloma.

The phase 3 IMvigor011 trial represents a landmark shift toward personalized, biomarker-driven adjuvant therapy in muscle-invasive bladder cancer.

Gemcitabine-iDRS did not show superior bladder-intact event-free survival over chemoradiotherapy and there were no patient subgroups that suggest further evaluation in subsequent studies.

Phase 2 Daro-PET tests short-course darolutamide to boost PSMA PET signal in high-risk localized prostate cancer, guiding improved imaging interpretation.

Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab and nivolumab in patients with metastatic RCC.

AI begins transforming precision oncology, speeding drug target discovery with AlphaFold and cutting clinical trial paperwork from months to days.

Trial finds CAR‑T approach shows minimal CRS and no neurotoxicity or prolonged cytopenia, enabling safer treatment for older, frail patients.

Final overall survival data for PEACE-3 (NCT02194842) evaluating the combination of enzalutamide (Xtandi) and radium-223 (Xofigo) will be presented at the 2026 ASCO GU Cancers Symposium.